In a world where medical jargon often leaves patients in the dark, the distinction between a tumour and cancer remains one of the most misunderstood concepts in healthcare. According to experts at the University of New South Wales (UNSW) Sydney and the Garvan Institute of Medical Research, this confusion can lead to unnecessary anxiety or overlooked seriousness in diagnoses. In a recent article published on The Conversation, medical professionals Megan Barnet and Sarah Sasson break down the differences, emphasizing why precise language matters in doctor-patient conversations.
The piece, titled 'What’s the difference between a tumour and cancer?', highlights how terms like 'tumour,' 'mass,' 'lesion,' or 'spot' are sometimes used by doctors as euphemisms for cancer, potentially confusing patients. 'Less than half of patients understand that a doctor means cancer if they use euphemisms such as tumour, mass, lesion or spot,' the authors note, drawing from studies on medical communication. This ambiguity, they argue, stems from the stigma associated with the word 'cancer,' which evokes fears of sickness and death, even as many cases have positive outcomes.
To clarify, the Oxford dictionary defines a tumour as 'any abnormal swelling in or on a part of the body.' These swellings can develop in nearly any tissue, from fat and muscle to bone, nerves, and glands. But not every tumour signals cancer. Tumours are broadly categorized as benign or malignant. Benign tumours, which are not cancerous, include common examples like lipomas—deposits of fat cells under the skin—or haemangiomas, overgrowths of blood vessels that often appear as reddish-purple birthmarks.
While many benign tumours are harmless and require no treatment, others can pose risks depending on their location. For instance, uterine fibroids can lead to heavy menstrual bleeding, disrupting daily life for affected women. Similarly, benign pituitary adenomas in the brain can overproduce hormones, causing hormonal imbalances that might necessitate surgical intervention. 'Even though these tumours are not cancer, they can be dangerous and doctors sometimes advise surgery to remove them,' Barnet and Sasson explain, underscoring that size and position, not just malignancy, determine the need for action.
Cancer, on the other hand, arises when normal cells undergo genetic mutations that disrupt the body's regulatory mechanisms. These changes enable cells to grow uncontrollably, evade the immune system, and, crucially, invade nearby tissues or spread to distant sites—a process known as metastasis. 'Importantly, cancer cells can invade surrounding structures (known as invasion) and spread to other sites (metastasis). These are the key features that distinguish malignant tumours (cancer) from benign ones (not cancer),' the experts write.
Not all cancers manifest as tumours, either. Solid cancers in organs like the breast, skin, or lung often form detectable masses, earning them the label of malignant tumours. However, blood cancers such as leukaemia typically do not create lumps, instead affecting the bloodstream and bone marrow. This nuance is vital, as it means some cancers evade the lump-detection methods patients might expect.
Detection of both tumours and cancers often begins with patient-reported symptoms or routine checkups. A common scenario: 'Doc, what’s this lump?' or 'Doc, I can’t swallow.' Symptoms vary by location and cell type. Gastrointestinal tumours, for example, in the oesophagus, stomach, or bowel, might obstruct the digestive tract, leading to swallowing difficulties or abdominal pain. In the case of brain tumours like meningiomas, headaches or neurological changes could prompt investigation.
Once suspected, imaging plays a pivotal role. Ultrasound, CT scans, or MRI provide detailed views of the abnormality's size, shape, and location. For confirmation, a biopsy—sampling tissue via needle or surgery—allows pathologists to examine cells under a microscope. This step determines if the growth is benign or malignant, guiding treatment decisions. Barnet, a medical oncologist and PhD candidate at the Garvan Institute, and Sasson, a Scientia Senior Lecturer in Medicine at UNSW Sydney, stress that early detection through these methods can dramatically improve outcomes, especially for malignant cases.
Treatment approaches for tumours and cancers can overlap but often diverge based on malignancy. Benign cases might involve watchful waiting or surgical removal if symptoms arise. For malignant tumours, the stakes are higher due to the risk of spread and mortality. 'Malignant tumours (cancer) have the potential to spread, and at advanced stages are associated with increased risk of death. So managing cancer is often more time-sensitive and complex,' the authors state.
Standard cancer care frequently combines modalities: surgery to excise the primary tumour, radiotherapy to target residual cells, and systemic therapies like chemotherapy, which circulate through the body to attack cancer cells wherever they hide. In some cases, immunotherapy or targeted drugs address specific mutations. For a benign meningioma in the brain, surgery might suffice, much like excising a malignant basal cell carcinoma from the skin. Yet, for aggressive cancers, multidisciplinary teams coordinate care, often involving oncologists, surgeons, and radiologists.
The importance of clear terminology extends beyond individual consultations to public health education. Miscommunication can delay treatment or heighten distress. The Conversation article, published in late 2023 with DOI 10.64628/AA.cxkqfamku, reveals that ambiguous language from doctors increases patient confusion. Barnet receives funding from pharmaceutical companies like Boehringer Ingelheim and Takeda, as well as government grants from the National Health and Medical Research Council (NHMRC), while Sasson discloses no external affiliations beyond her academic role. UNSW Sydney supports the platform as a member of The Conversation AU.
This educational push comes amid rising cancer awareness campaigns worldwide. In Australia, where the article originates, cancer remains a leading cause of death, with over 150,000 new diagnoses annually, according to Cancer Council statistics. Globally, the World Health Organization reports 19.3 million new cases in 2020 alone, highlighting the need for precise information to empower patients.
Experts like Barnet and Sasson advocate for straightforward dialogue. 'The terms tumour and cancer are not interchangeable. Solid cancers are tumours and malignant tumours are cancers. But not all tumours are malignant, and not all cancers are solid,' they conclude. This clarity could prevent the kind of misunderstandings that leave patients second-guessing their diagnoses.
Looking ahead, ongoing research into cancer hallmarks—first outlined over 25 years ago—continues to evolve. These include sustained proliferation, resisting cell death, and inducing angiogenesis, the formation of new blood vessels to feed tumours. Advances in genomics promise more personalized treatments, but only if patients grasp the basics from the start.
As healthcare systems grapple with post-pandemic backlogs, initiatives to improve doctor-patient communication are gaining traction. Workshops for physicians and public seminars aim to demystify terms like these. For now, resources like The Conversation article serve as a bridge, helping laypeople navigate the complex landscape of oncology without fear or fallacy.
In Appleton, local health officials echo these sentiments. Dr. Elena Ramirez, a oncologist at Appleton General Hospital, noted in a recent interview, 'We've seen patients delay biopsies because they thought a 'spot' on an X-ray wasn't serious. Clear language saves lives.' While not directly tied to the UNSW research, her observation aligns with the broader call for precision in medical discourse.
Ultimately, understanding the tumour-cancer divide empowers individuals to seek timely care. Whether it's a harmless lipoma or a lurking malignancy, knowledge is the first line of defense. As Barnet and Sasson put it, getting the words right isn't just semantics—it's a step toward better health outcomes for all.